As of June 30, 2026, Cellbion Co., Ltd carries a market capitalization of 215.18B, placing it among publicly traded companies globally. Its enterprise value stands at 161.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 215.18B |
| Enterprise Value | 161.29B |
As of June 30, 2026, Cellbion Co., Ltd has 12.83M shares outstanding.
| Shares Outstanding | 12.83M |
As of June 30, 2026, Cellbion Co., Ltd trades at a trailing price-to-earnings ratio of 27.78. The price-to-sales ratio is 100.35, and the price-to-book ratio stands at 5.96.
| PE Ratio | 27.78 |
| PS Ratio | 100.35 |
| PB Ratio | 5.96 |
| P/TBV Ratio | 6.08 |
| P/FCF Ratio | -20.20 |
| P/OCF Ratio | -31.63 |
These figures are as of June 30, 2026. The EV/Sales ratio of 75.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 161.29B versus a market cap of 215.18B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 75.17 |
As of June 30, 2026, Cellbion Co., Ltd maintains a current ratio of 33.44, meaning it holds 33.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.08, indicating elevated leverage, while an interest coverage ratio of -13.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 33.44 |
| Quick Ratio | 32.53 |
| Debt / Equity | 38.08 |
| Debt / EBITDA | -1.63 |
| Interest Coverage | -13.18 |
Over the twelve months ended June 30, 2026, Cellbion Co., Ltd posted a return on equity (ROE) of 24.80, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -24.34, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 13.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.28, useful for judging operating efficiency across full business cycles. The company generates approximately 38.31M in revenue per employee across its workforce of 56.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.47 indicates how many times Cellbion Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 24.80 |
| Return on Assets (ROA) | 13.46 |
| Return on Invested Capital (ROIC) | -24.34 |
| Return on Capital Employed (ROCE) | 21.28 |
| Revenue Per Employee | 38.31M |
| Employee Count | 56.00 |
| Inventory Turnover | 5.47 |
As of the close on November 17, 2026, Cellbion Co., Ltd's stock has declined approximately 42.78% over the past 52 weeks. The 50-day moving average sits at 12,794.60, while the 200-day moving average is 20,606.90.
| 52-Week Price Change | -42.78% |
| 50-Day Moving Average | 12,794.60 |
| 200-Day Moving Average | 20,606.90 |
Over the twelve months ended June 30, 2026, Cellbion Co., Ltd generated 2.15B in revenue and converted that into 7.75B in net income, yielding earnings per share of 591.05. EBITDA reached -8.42B, while operating income came in at -9.59B.
| Revenue | 2.15B |
| Gross Profit | -97.00M |
| Operating Income | -9.59B |
| Pretax Income | 7.75B |
| Net Income | 7.75B |
| EBITDA | -8.42B |
| EBIT | -9.59B |
| Earnings Per Share (EPS) | 591.05 |
As of June 30, 2026, Cellbion Co., Ltd holds 67.65B in cash and equivalents against 13.76B in total debt, resulting in a net debt position of 5.33B. Total book value stands at 36.13B, with working capital of 67.48B providing operational flexibility.
| Cash & Cash Equivalents | 67.65B |
| Total Debt | 13.76B |
| Net Debt | 5.33B |
| Equity (Book Value) | 36.13B |
| Book Value Per Share | 2,815.62 |
| Working Capital | 67.48B |
Cellbion Co., Ltd produced -6.81B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.08B in capital expenditures, free cash flow totaled -10.89B - equivalent to -848.08 per share.
| Operating Cash Flow | -6.81B |
| Capital Expenditures | -4.08B |
| Free Cash Flow | -10.89B |
| FCF Per Share | -848.08 |
Over the twelve months ended June 30, 2026, Cellbion Co., Ltd posted a gross margin of -4.52, reflecting its pricing power and cost economics. The operating margin of -447.16 and net profit margin of 361.23 provide insight into operational efficiency.
| Gross Margin | -4.52 |
| Operating Margin | -447.16 |
| Pretax Margin | 361.23 |
| Profit Margin | 361.23 |
| EBITDA Margin | -392.37 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -23.36, meaning Cellbion Co., Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -23.36 |
| FCF Yield | -4.95 |
As of June 30, 2026, Cellbion Co., Ltd has an Altman Z-Score of 2.70, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.70 |
Already premium?